Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-12-03T19:26:17.114Z Has data issue: false hasContentIssue false
  • English
  • Français

Switching Antidepressants vs. Conventional Augmentation Strategies

Published online by Cambridge University Press:  07 November 2014

George I. Papakostas
Get access Rights & Permissions [Opens in a new window]

Extract

Antidepressants have been available since the 1950s, when the monoamine oxidase inhibitors were first discovered. Since then, our armamentarium of antidepressants has progressively expanded with the discovery of the tricyclic antidepressants (TCAs) in the 1960s, the selective serotonin reuptake inhibitors (SSRIs) in the 1980s, and, subsequently, the serotonin norepinephrine reuptake inhibitors (SNRIs), and other agents possessing a diverse mechanism of action including buproprion, and mirtazapine.

Type
Expert Panel Supplement
Information
CNS Spectrums , Volume 14 , Issue S4: Pharmacologic and Therapeutic Strategies in Treatment-Resistant Depression , March 2009 , pp. 11 - 14
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Papakostas, GI, Fava, M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19:34–40.CrossRefGoogle ScholarPubMed
2.Petersen, T, Papakostas, GI, Posternak, MA, et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol. 2005;25(4):336–341.CrossRefGoogle ScholarPubMed
3.Shelton, RC, Papakostas, GI. Augmentation of antidepressants with atypical anti-psychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand. 2008;117(4):253–259.CrossRefGoogle Scholar
4.Papakostas, GI, Fava, M. Monoaminergic-based Pharmacotherapy for Depression. In: Licinio, J, Wong, M, eds. Biology of Depression. From Novel Insights to Therapeutic Strategies. 1st ed.Weinheim, Germany. Wiley-VCH Verlag; 2005:87–140.CrossRefGoogle Scholar
5.Richelson, E, Souder, T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68(1):29–39.CrossRefGoogle ScholarPubMed
6.Shapiro, DA, Renock, S, Arrington, E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28(8):1400–1411.CrossRefGoogle ScholarPubMed
7.Piñeyro, G, Blier, P. Regulation of 5-hydroxytryptamine release from rat midbrain raphe nuclei by 5-hydroxytryptamine1D receptors: effect of tetrodotoxin, G protein inactivation and long-term antidepressant administration. J Pharmacol Exp Ther. 1996;276(2):697–707.Google ScholarPubMed
8.Bielski, RJ, Cunningham, L, Horrigan, JP, et al. Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study. J Clin Psychiatry. 2008;69(4):571–577.CrossRefGoogle ScholarPubMed
9.Blier, P, Ward, NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry. 2003;53(3):193–203.CrossRefGoogle Scholar
10.Feiger, AD, Heiser, JF, Shrivastava, RK, et al. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry. 2003;64(3):243–249.CrossRefGoogle ScholarPubMed
11.Robinson, DS, Sitsen, JM, Gibertini, M. A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone. Clin Ther. 2003;25(6):1618–1633.CrossRefGoogle ScholarPubMed
12.Schmidt, AW, Lebel, LA, Howard, HR Jr., Zorn, SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425(3):197–201.CrossRefGoogle ScholarPubMed
13.Burris, KD, Molski, TF, Xu, C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302(1):381–389.CrossRefGoogle ScholarPubMed
14.Ostroff, RB, Nelson, JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 1999;60(4):256–259.CrossRefGoogle ScholarPubMed
15.Shelton, RC, Tollefson, GD, Tohen, M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158(1):131–134.CrossRefGoogle ScholarPubMed
16.Corya, SA, Williamson, D, Sanger, TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety. 2006;23(6):364–372.CrossRefGoogle ScholarPubMed
17.Shelton, RC, Williamson, DJ, Corya, SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry. 2005;66(10):1289–1297.CrossRefGoogle ScholarPubMed
18.Thase, ME, Corya, SA, Osuntokun, O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007;68(2):224–236.CrossRefGoogle ScholarPubMed
19.Keitner, GI, Garlow, SJ, Ryan, CE, et al. A randomized, placebo-controlled trial of ris-peridone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res. 2009;43(3):205–214.CrossRefGoogle ScholarPubMed
20.Mahmoud, RA, Pandina, GJ, Turkoz, I, et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med. 2007;147(9):593–602.CrossRefGoogle ScholarPubMed
21.Khullar, A, Chokka, P, Fullerton, D, McKenna, S, Blackman, A. Quetiapine as treatment of non-psychotic unipolar depression with residual symptoms: double blind, randomized, placebo controlled study. Paper presented at: Annual Meeting of the American Psychiatric Association; May 22, 2006; Toronto, Canada.Google Scholar
22.Mattingly, GW, Ilivicky, HJ, Canale, JP, Anderson, RH. Quetiapine augmentation for treatment-resistant depression. Paper presented at: Annual Meeting of the American Psychiatric Association; May 22, 2006; Toronto, Canada.Google Scholar
23.McIntyre, A, Gendron, A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venla-faxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 2007;24(7):487–494.CrossRefGoogle ScholarPubMed
24.Papakostas, GI, Shelton, RC, Smith, J, Fava, M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007;68(6):826–831.CrossRefGoogle ScholarPubMed
25.Berman, RM, Marcus, RN, Swanink, R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, doubleblind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843–853.CrossRefGoogle ScholarPubMed
26.Marcus, RN, McQuade, RD, Carson, WH. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156–165.CrossRefGoogle ScholarPubMed
27.Bauer, M, Pretorius, HW, Earley, W, Lindgren, P, Brecher, M. Results from a phase III study of extended release quetiapine fumarate (quetiapine XR) as add-on to antidepressants in patients with major depressive disorder (MDD). Poster presented at: The 7th International Forum on Mood and Anxiety Disorders; December 5–7, 2007; Budapest, Hungary.CrossRefGoogle Scholar
28.El-Khalili, N, Joyce, M, Atkinson, S, et al. Adjunctive ER quetiapine fumarate (XR) in patients with major depressive disorder and inadequate antidepressant response. Paper presented at: Annual Meeting of the American Psychiatric Association; May 5, 2008; Washington, DC.Google Scholar
29.Henderson, DC, Doraiswamy, PM. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry. 2008;69(suppl 1):32–44.Google ScholarPubMed
30.Weiden, PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007;13(1):13–24.CrossRefGoogle Scholar
31.Johnsen, E, Jørgensen, HA. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry. 2008;8:31.CrossRefGoogle ScholarPubMed
32.Rapaport, MH, Gharabawi, GM, Canuso, CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology. 2006;31(11):2505–2513.CrossRefGoogle ScholarPubMed